Alacris Theranostics GmbH is a pioneer in the field of Next Generation Sequencing based treatment guidance, clinical trial stratification and biomarker discovery. The company holds an exclusive worldwide license for ModCellTM, a computer modelling system that addresses a critical bottleneck in the development of personalised health care solutions. Alacris Theranostics uses this technology to match patients to drugs and the right set of patients to a specific treatment, the latter for clinical trial stratification and biomarker identification. The company currently markets its technologies to a range of customers from private individuals, academic researchers and hospitals to biotechnology and pharmaceutical companies.

Since it was founded in 2008, Alacris Theranostics has attracted strategic investment from Qiagen and is the recipient of numerous competitive international and national research grants, including including those from the EU Horizon 2020 Programme, the EU Seventh Framework Programme (FP7), the Innovative Medicines Initiative (IMI) and the European Fund for Regional Investment. Current sources of grant funding also include the German Federal Ministry of Education and Research (BMBF) and the Investitionsbank Berlin (IBB) through its GRW (Gemeinschaftsaufgabe “Verbesserung der regionalen Wirtschaftsstruktur“) initiative.

To discuss investment opportunities, please contact us.


BMBF
IBB
IMI
Europa
EFRE
Stifterverband
FP7
Qiagen